Is this message not displayed correctly?
Please click here for the online version.
|
|
Dear Sir or Madam, Cell and gene therapies have the potential to profoundly transform medicine in the future. They offer new possibilities for treating previously incurable diseases and improving the quality of life for many patients. As research and technology advance, these therapies are becoming increasingly safer, more effective, and more accessible, promising a bright future for healthcare. Berlin is on its way to becoming a leading hub in Germany and Europe. This was particularly evident during two high-profile political events: On June 12, the Berlin Institute of Health at Charité (BIH) presented the National Strategy for Gene- and Cell-Based Therapies to Federal Research Minister Bettina Stark-Watzinger in Berlin in the presence of numerous parliamentarians. Just a few days later, on June 21, Charité and Bayer unveiled their concept for a Translational Center for Gene and Cell Therapies to the Federal Chancellor, the Governing Mayor of Berlin, several senators, state secretaries, and the specialized public. There are also positive business developments: For example, the Berlin-based company Captain T Cell secured €8.5 million in funding, Bayer and BlueRock Therapeutics received approval for their cell therapy against Parkinson's disease in the USA, and the MDC-Bruker Center was opened on July 8 as an innovation center for systems medicine. With its research landscape and innovative companies, the capital region is well-positioned to set new standards in gene and cell therapies. We are excited to continue supporting these initiatives! Please mark your calendars: Our next BIONNALE will take place in May 14/15, 2025 in Berlin. Warm regards, Your Dr. Kai Uwe Bindseil Berlin Partner for Business and Technology |
|
„Berlin is the best place for AI startups in Germany” Dr. Uirá Souto Melo, a native Brazilian, did his PhD in the field of genetics at University of São Paulo. In 2018 he moved to Berlin to work as a scientist at the Max-Planck-Institute. His research focused mostly on dark genome, the relatively unknown long stretches of non-coding DNA. In 2024 he and Dr. M-Hossein Moeinzadeh founded the startup company Lucid genomics. |
|
|
The Barcamp Health Innovation raises important issues regarding the patient journey For many patients, their treatment is the start of a long journey through the health system. This is often referred to as the patient journey and includes all stages in connection with a disease, from prevention to recovery or the ongoing management of a chronic disease. This year’s Barcamp Health Innovation was dedicated to this patient journey, which is becoming increasingly important for stakeholders in the health segment. A great variety of participants from the sectors industry, science and medical care illuminated the topic from different perspectives. |
|
|
FDPG: a unique data portal for medical research In many cases, it is problematic to obtain relevant and comparable data for research projects in Germany. Politics is aware of this problem, and since 2018, the Medical Informatics Initiative, initiated by the German Federal Ministry of Education and Research, has been working on solutions. In this context, the German Portal for Medical Research Data (FDPG) was created, which provides researchers with centralized access to important routine health care data. |
|
|
Berlin-Brandenburg: an international start-up hotspot in the digital health segment Berlin-Brandenburg is home to more than 700 start-ups and scale-ups in the digital health segment. This is the result of the stocktaking by Cluster HealthCapital on the region’s digital health ecosystem. A considerable number that was certainly not achieved just like that. That is why we talked to Tim Huse about what makes the region so successful at attracting digital health start-ups. Mr. Huse is Head of BIH Digital Health Accelerator at the Berlin Institute of Health @ Charité and accompanied many start-ups on their way from research player to market participant. |
|
|
The tip from our relocation experts:
Berlin Partner’s Economy Overview Map – a helpful tool when deciding on the perfect location In order to decide which address and area of the city to choose when relocating to Berlin, the Economy Overview Map is a very useful resource. With this tool you can discover Berlin in 3D (including major ongoing building projects), get an overview of companies/academia from a specific industry, find co-working spaces and determine the distance from your home to your workplace by car and public transport options. Our location team and I are happy to answer any questions you might have in this regard. Flavia Kruse Berlin Partner for Business and Technology MedTech | Healthcare | Digital Health 📧 |
|
|
|
|
Bayer's Expert Mondays 2024 - Demystify Due Diligence with Big Pharma
|
|
World Health Summit 2024
October 13-15, 2024 | Berlin Read more |
|
The MedTech Conference
October, 15-17, 2024 | Toronto, Canada Meet us and our Berlin delegation companies during our pitch session at the ‘Doing Business Globally Program’ on Monday, Oct. 14th starting at 3:10pm Read more |
|
Frontiers Health 2024
October 17-18 | Berlin
Read more
|
|
MEDICA 2024
November, 11-14, 2024 | Düsseldorf, Germany Read more |
|
“The Product is the Process – Is it?” Manufacturing and Translation of ATMP and Tissue-& Cell-based products
November 28, 2024 | Potsdam Read more |
|
RegMed Forum 2025: Process development and translation of ATMP projects
February 27, 2024 | Berlin Read more |
|
BIONNALE 2025
May 14/15, 2025 | Berlin Read more |
|
For more events in the life science region Berlin-Brandenburg click here. |
|
Berlin Center for Gene and Cell Therapies kicked off in Berlin Today Bayer AG, together with Charité – Universitätsmedizin Berlin, presented plans for the construction of the Berlin Center for Gene and Cell Therapies. The project is being substantially financed and supported by Germany’s Federal Government as well as the State of Berlin. The aim of the joint project is to bring these groundbreaking technologies to patients more quickly while creating a leading biotech ecosystem for innovative therapies in Berlin.
|
|
|
Caresyntax Raises $180 Million Funding to Accelerate Growth and Adoption of Precision Surgery Caresyntax, a vendor-neutral precision surgery platform, is pleased to announce raising a total commitment of $180 million through a series C extension and growth debt expansion round. Investors in the $180 million round include Symbiotic Capital, MTIP AG, BIONIQ Capital, PFM Health Sciences, Pictet Alternative Advisors, surgical.ai, BlackRock Innovation Capital, Aescuvest, Optum Ventures, Cure Capital, Relyens Group, Vesalius Biocapital, Lauxera Capital, Plug & Play Growth Fund, and ProAssurance Corp. The financing comprises $80M of equity and up to $100M of growth debt facility.
|
|
|
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease cell therapy candidate bemdaneprocel
Read more |
|
MSD launches IDEA Studios in Berlin
Read more |
|
Tacalyx extends Seed Round to over €14 M to Advance Development of its Cancer Therapeutics Targeting TACAs
Read more |
|
SphingoTec Closes €5M Series C to Accelerate Market Development and Financial Growth with Innovative Biomarkers
Read more |
|
Berlin startup Lucid Genomics secures pre-seed funding of €1.3 million to fine-tune their AI models for diagnostics and biomarker identification
Read more |
|
Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study
Read more |
|
Science and Technology News
|
|
|
HIV cured at Charité: the next Berlin patient He went down in medical history: the “Berlin Patient,” the first person in the world to be cured of HIV, following a stem cell transplant at Charité – Universitätsmedizin Berlin. Now, a team from Charité has repeated this extremely rare medical achievement. The second Berlin patient has had no detectable virus for more than five years even though he is not taking antiviral medications. What makes this case special is that the team used a treatment method different from previous cases in which patients have been cured of HIV. It necessitates a new explanation of the mechanism by which the virus was cured.
|
|
|
Robotics in care: Pilot study on interaction with social robot Pepper How can social robots be effectively integrated into everyday care to improve the supervision and support of senior citizens? The results of a current study at the Brandenburg University of Technology Cottbus-Senftenberg (BTU) should shed light on this.
|
|
|
Surprising mechanism of lupus kidney damage identified A team led by Charité – Universitätsmedizin Berlin, German Rheumatology Research Center (DRFZ) and Max Delbrück Center have defined key cells behind severe kidney damage in lupus. The research, published in Nature,could inform future antibody therapies.
|
|
|
New perspectives for patients: National Strategy for Gene and Cell Therapies presented to the BMBF
Read more |
|
Novel Cancer Therapeutic from FMP Research enters clinical phase
Read more |
|
Proteins in the blood can predict the risk of developing more than 60 diseases
Read more |
|
New Molecular Insights into Bariatric Surgery's Impact on Obesity and Type 2 Diabetes
Read more |
|
When is the best time of day for cancer treatment?
Read more |
|
Technology and Cooperation Offers
|
|
|
Diagnostic assay for determination of personal microbial metabolite production profile for nutritional adjustment
Read more |
|
For more news from the cluster healthcare industries click here. |
|
|
EDITOR | IMPRINT
This newsletter is operated by the cluster healthcare industries
Berlin-Brandenburg HealthCapital.
Berlin Partner for Business and Technology
Fasanenstrasse 85 | 10623 Berlin | Germany
Phone: +49 30 46302-463
Email: info (at) healthcapital.de
Commercial Registry Entry
Entered in the commercial registry of the Charlottenburg District Court,
Registration number: HRB 13072 B
VAT ID: DE 136629780
CEO: Dr. Stefan Franzke
Chairman of the Supervisory Board: Carsten Jung
© 2024 Berlin Partner for Business and Technology
|
|
The newsletter of the Cluster healthcare industries Berlin-Brandenburg is a project of Berlin Partner for Business and Technology.
|
|
|
You have been forwarded this newsletter and would like to subscribe?
Please click here.You want to unsubscribe from the newsletter (to: unknown@noemail.com)? Please click here.
|
|
|
|
|
